UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.

UBT251 achieved up to a 19.7% reduction in body weight in adults with overweight or obesity over 24 weeks, significantly exceeding placebo with all p < 0.001.

• Why it matters: Effective weight loss treatments with cardiometabolic benefits are needed for adults with overweight or obesity without type 2 diabetes, addressing a major health concern.
• What they did: Researchers conducted a multicenter, randomized, double-blind, placebo-controlled phase 2 trial involving 205 adults receiving weekly UBT251 at doses of 2 mg, 4 mg, or 6 mg, or placebo for 24 weeks.
• The result: UBT251 led to substantial weight loss and improvements in waist circumference, BMI, blood pressure, lipids, and glycemic parameters, with mostly mild-to-moderate gastrointestinal side effects, supporting further phase 3 studies.